EVT 201

DB05721InvestigationalSmall molecule

EVT 201 is a novel partial positive allosteric modulator of the GABAA receptor complex which is being developed as a treatment for insomnia. It is being developed by Evotec Inc.

Mechanism: EVT 201 is a partial positive allosteric modulator (pPAM) of the GABAA receptor complex and consequently works through a proven pathway in the treatment of insomnia. However, EVT 201’s partial agonist activity gives it a differentiated pre-clinical profile and mechanism of action compared to many currently marketed sleep-promoting agents.
Curator reviewed
Primary indication: Investigated for use/treatment in insomnia.Curator reviewed
Formula / weight: C₁₇H₁₇ClN₆O₂ · 372.81 g/mol (avg)
Code names: EVT-201

Resolves to

Compound

UNII6J8AF7CLE4CAS308239-86-3

Structure

InChIKeyJCYLWUVDHLVGER-UHFFFAOYSA-NSMILESCN(C)CC1=NC(=NO1)C1=C2CN(C)C(=O)C3=C(C=CC=C3Cl)N2C=N1

Targets

P14867GABRA1Q99928GABRG3

What you can answer from here — as of January 29, 2025

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with EVT 201, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account